EP1185287A2 - Recepteur d'oestrogenes - Google Patents

Recepteur d'oestrogenes

Info

Publication number
EP1185287A2
EP1185287A2 EP00940530A EP00940530A EP1185287A2 EP 1185287 A2 EP1185287 A2 EP 1185287A2 EP 00940530 A EP00940530 A EP 00940530A EP 00940530 A EP00940530 A EP 00940530A EP 1185287 A2 EP1185287 A2 EP 1185287A2
Authority
EP
European Patent Office
Prior art keywords
erα
erko
derko
antagonist
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00940530A
Other languages
German (de)
English (en)
Inventor
Claes Department of Internal Medicine OHLSSON
Jan Ake Dept. Medical Nutritition GUSTAFSSON
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Karo Healthcare AB
Original Assignee
Karo Bio AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Karo Bio AB filed Critical Karo Bio AB
Publication of EP1185287A2 publication Critical patent/EP1185287A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders

Definitions

  • ER ⁇ is expressed in growth plate chondrocytes and osteoblasts, indicating a possible role for ER ⁇ in the regulation of longitudinal bone growth and/or adult bone metabolism (Onoe, Y., et al (1997) Endocrinology 138, 4509-4512, Arts, J., Kuiper, G.G., et al (1997) Endocrinology 138, 5067-5070, Vidal, O., et al (1999) J Bone Miner Res In press, Nilsson, L.O., et al (1999) J Clin Endocrinol Metab 84, 370-373; Windahl own unpublished results).
  • mice devoid of functional ER ⁇ protein have recently generated mice devoid of functional ER ⁇ protein and reported that ER ⁇ is essential for normal ovulation efficiency, but is not essential for female or male sexual development, fertility, or lactation (Krege, J.H., et al (1998) Proc Natl Acad Sci US A 95, 15677-15682).
  • ER ⁇ and ER ⁇ have almost identical DNA-binding domains and studies in vitro have demonstrated that the two receptors have similar affinities for estrogenic compounds (Kuiper, G.G. et al (1996) Proc Natl Acad Sci U S A 93, 5925-5930, Kuiper, G.G., et al (1997) Endocrinology 138, 863-870, Tremblay, G.B., et al (1997) Mol Endocrinol 11, 353-365).
  • the amino-acid sequence of ER ⁇ differs from ER ⁇ in the N- and C-terminal trans-activating regions.
  • Ornoy et al showed that orchidectomy in mice decreases growth plate area measured in the proximal tibia and that low-dose estrogen treatment increases the same parameter (Ornoy, A et al (1994) supra). These findings demonstrate that physiological levels of estrogen have a stimulatory effect on longitudinal growth in male rodents. Similarly, estrogens are required for the pubertal growth spurt in boys (MacGillivray, M. H. et al (1998) Horm. Res. 49 Suppl 1, 2-8). Estrogen regulates final height in humans by a stimulatory effect on the pubertal growth spurt, followed by closure of the epiphyseal growth plates at the end of puberty. In humans with estrogen deficiency or estrogen resistance growth plate fusion never occurs.
  • Bone loss following gonadal deficiency is normally associated with increased bone turnover.
  • osteocalcin a marker for bone formation
  • This finding and the pronounced cortical osteopenia seen in ERKO and DERKO males led us to seek other explanations to the skeletal phenotype in these mice.
  • Over-all size and cortical radial growth are parameters that are highly sensitive to changes in the GH/IGF-I axis (Andreassen, T. T. (1995) J. Bone. Miner Res. 10 1057-1067, Ohlsson, C. et al (1998) Endocr. Rev. 19 55-79; Rosen, H. N. et al (1995) J. Bone. Miner.
  • Endocrinol Metab. 62, 159-164 The mechanism whereby testosterone interacts with the somatotropic axis may either be direct, mediated by androgen receptors, or indirect through the action of estrogen on estrogen receptors.
  • estrogen mediates the effects of testosterone on the somatotropic axis has been suggested in a previous study showing a significant correlation between circulating levels of estrogen, but not testosterone, and GH secretion in men (Ho. K. Y. et al (1987) J. Clin. Endocrinol Metab. 64, 51-58).
  • testosterone plays an important role in the modulation of the somatotropic axis in adulthood and this effect is, at least partly, dependent on the conversion of testosterone to estrogen (Weissberger, A. J. et al (1993) J. Clin. Endocrinol. Metab 76, 1407-1412).
  • some of the skeletal effects seen in ER ⁇ inactivated male mice may be due to an inhibition of the GH IGF-I axis.
  • a method of treating growth disorders in a mammal comprising treating the mammal with an ER ⁇ -specific agonist.
  • a method of treating growth disorders in a mammal comprising treating the mammal with an ER ⁇ -specific antagonist.
  • the mammal may be male or female and is preferably pre-pubesent.
  • an ER ⁇ selective antagonist in the preparation of a medicament for the treatment of a growth disorder.
  • a pharmaceutical composition suitable for treating or preventing growth disorders in a mammal comprising an ER ⁇ antagonist or agonist.
  • the ER ⁇ agonist or antagonist has a binding affinity for ER ⁇ of less than 10 nM, most preferably 0.0001 to 10 nM.
  • compositions of this invention comprise any of the compounds of the present invention, and pharmaceutically acceptable salts thereof, with any pharmaceutically acceptable carrier, adjuvant or vehicle.
  • Pharmaceutically acceptable carriers, adjuvants and vehicles that may be used in the pharmaceutical compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulphate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.
  • the pharmaceutical compositions may be in the form of a sterile injectable preparation, for example, as a sterile injectable aqueous or oleaginous suspension.
  • This suspension may be formulated according to techniques known in the art using suitable dispersing or wetting agents (such as, for example, Tween 80) and suspending agents.
  • the sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally-acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
  • suitable vehicles and solvents that may be employed are mannitol, water, Ringer's solution and isotonic sodium chloride solution.
  • sterile, fixed oils are conventionally employed as a solvent or suspending medium.
  • any bland fixed oil may be employed including synthetic mono- or diglycerides.
  • Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or caster oil, especially in their polyoxyethylated versions.
  • These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant such as Ph. Helv or a similar alcohol.
  • compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, and aqueous suspensions and solutions.
  • carriers which are commonly used include lactose and corn starch.
  • Lubricating agents such as magnesium stearate, are also typically added.
  • useful diluents include lactose and dried corn starch.
  • aqueous suspensions are administered orally, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening and or flavoring and/or colouring agents may be added.
  • a method of selecting compounds for the regulation of body growth in mammals comprising selecting a compound on the basis of its ability to antagonise agonist-dependent ER ⁇ activity.
  • a method of selecting compounds for the use in the treatment of growth disorders comprising testing the compound in a mammal which is wholly or partially ER ⁇ deficient or in cells derived from such an animal.
  • a method of treating a bone mineral density disorder in a mammal comprising treating the mammal with an ER ⁇ -specifc agonist.
  • the invention provides a method of treating a bone mineral density disorder in a mammal, the method comprising treating the mammal with an ER ⁇ -specific antagonist.
  • the ER ⁇ -specific ligand modulator may be a SERM, the mammal may be a male or female and may be pre-pubesent.
  • the ER ⁇ agonist or antagonist may have a binding affinity of less than 10 nM, preferably 0.0001 to 10 nM or ER ⁇ .
  • Fig. 8 illustrates the effects of androgens in the male mouse skeleton.
  • AR androgen receptor
  • ER ⁇ estrogen receptor- ⁇
  • ER ⁇ estrogen receptor- ⁇ .
  • the length of the femur was unchanged at the prepubertal stage (Fig 3A, day 31, one-way ANOVA). Thereafter ⁇ RKO and D ⁇ RKO demonstrated a gradual decrease in growth rate, resulting in a decreased femoral length at the adult stage ( ⁇ RKO -5.7%, D ⁇ RKO -4.4% versus WT, Fig 3A, 5A).
  • the decreased growth of the long bones in ERKO and DERKO was associated with a decreased growth plate width measured in the proximal tibia (Fig 3C).
  • the CR length was also decreased in ERKO and DERKO compared with WT (Fig 3B).
  • the DXA technique gives the areal BMD whereas the pQCT gives the true volumetric BMD. Therefore a factor regulating the outer dimensions of a bone, will affect the areal BMD (DXA) but not the volumetric BMD (pQCT).
  • Bone Histomorphometry The areas of trabecular bone within a reference area of the proximal tibia were measured in sections stained with Hematoxylin/Eosin. Measurements were performed on printed copies by point counting using a square lattice (1 and 2 cm). Three fields of vision on three sections from each animal were used for the analysis. Data is presented as the ratio of trabecular bone volume (BV) to total volume (TV).
  • Dynamic measurements were first analysed by a two-way analysis of variance (A OVA) followed by Student Newman Keuls multiple range test. Static measurements (at the time of sacrifice) were first analysed by one-way ANOVA followed by Student Newman Keuls multiple range test.
  • BMC/body weight was calculated for the whole skeleton and for individual bones.
  • BMC/body weight was decreased in ERKO (-18%) and DERKO (-22%) when compared to WT. This was also the case for femur (ERKO -20; DERKO -19%) and spine (ERKO -21%; DERKO -18%; Fig 5B).
  • Cortical endosteal circumference (mm) 4.31 ⁇ 0.13 3.89 ⁇ 0.05* 4.28 ⁇ 0.09 4.0210.11 Values are given as means 1 SEM. Data were first analysed by a one-way analysis variance followed by followed by Student Newman Keuls multiple range test. * p ⁇ 0.05. ** p ⁇ 0.01 versus WT.
  • BV/TV trabecular bone volume/total volume
  • Cortical bone parameters were studied in detail in mid-diaphyseal pQCT scans of femora and tibiae (Table 2, Fig 6B and data not shown).
  • the cortical BMC in the mid-diaphyseal section of femur was decreased in ERKO (-14%) and DERKO (-14%) compared with WT and this decrease was mainly due to a decreased cross-sectional bone area whereas cortical volumetric density was unchanged (Table 2).
  • the decrease in cross sectional area in ERKO and DERKO was associated with decreased periosteal and endosteal circumference (Fig 6B and Table 2).
  • IGF-I (ng/ml) 337136 25018* 313112 26416
  • the weights of several other organs were measured to see if the effect on the skeleton in ERKO and DERKO was tissue specific. To compare the relative growth of different organs the individual organ weights were divided with the total body weight. The weights of the liver, kidney, brain and testis were not significantly changed in any group. However, the weights of heart and lung were decreased in the ERKO compared with WT (heart -15%, lung -17%), Fig 7). In the results shown in Fig. 7, values are given as means 1 SEM. Data were first analysed by a one-way analysis of variance followed by Student Newman Keuls multiple range test. * p ⁇ 0.05 versus WT. These experiments demonstrate that ER ⁇ but not ER ⁇ is involved in the regulation of pubertal growth and adult bone mineral density in male mammals such as mice.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Les androgènes régulent le squelette du mâle directement, par la stimulation de récepteurs d'androgènes, et indirectement, par l'aromatisation d'androgènes et par leur transformation en oestrogènes suivie de la stimulation des récepteurs d'oestrogènes (RO). Afin d'étudier dans le détail l'importance relative des sous-types de récepteurs oestrogènes dans la régulation du squelette mâle, on a comparé les phénotypes du squelette des souris de type sauvage (TS), ROα, Knock-out (ROKO), ROβ Knock-out (BROKO) et ROα/β Double Knock-out (DROKO). ROKO et DROKO ont un poids corporel réduit et une croissance longitudinale d'os moins importante. En outre, ROKO et DROKO mais pas BROKO manifestent une diminution prononcée de la teneur minérale dans les os longs et le squelette axial. Cette diminution de la teneur minérale des os est due à l'ostéopénie corticale causée par une croissance radicale des os moins importante. Des tests mécaniques ont montré que le fémur des ROKO est plus faible, ce qui est une conséquence du changement des dimensions de l'os cortical. Dans aucun groupe, on n'a remarqué aucun changement notable au niveau de la densité osseuse trabéculaire. Les ROKO ont manifesté des taux de sérum réduits en ostéocalcine et en IGF-I. En outre, les taux de sérum en IGF-I ont été corrélés avec la plupart des changements au niveau du squelette que l'on a vu chez DROKO et ROKO. On peut en conclure que les phénotypes squelettiques des DROKO et des ROKO sont similaires et peuvent être clairement distingués du TS et des BROKO. Ainsi, c'est le récepteur ROα mais non pas celui ROβ qui sert de médiateur de l'effet de l'oestrogène dans le squelette de la souris.
EP00940530A 1999-06-11 2000-06-12 Recepteur d'oestrogenes Withdrawn EP1185287A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9913649 1999-06-11
GBGB9913649.1A GB9913649D0 (en) 1999-06-11 1999-06-11 Estrogen receptor
PCT/GB2000/002283 WO2000076529A2 (fr) 1999-06-11 2000-06-12 Recepteur d'oestrogenes

Publications (1)

Publication Number Publication Date
EP1185287A2 true EP1185287A2 (fr) 2002-03-13

Family

ID=10855195

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00940530A Withdrawn EP1185287A2 (fr) 1999-06-11 2000-06-12 Recepteur d'oestrogenes

Country Status (5)

Country Link
EP (1) EP1185287A2 (fr)
AU (1) AU5545400A (fr)
CA (1) CA2376441A1 (fr)
GB (1) GB9913649D0 (fr)
WO (1) WO2000076529A2 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
US6835745B2 (en) 2002-01-15 2004-12-28 Wyeth Phenyl substituted thiophenes as estrogenic agents
BRPI0514974A (pt) 2004-09-07 2008-07-01 Wyeth Corp composto, composição, métodos de tratar ou inibir uma doença ou condição, estados de doença induzidos por radical livre em um mamìfero, dano à junta secundário aos procedimentos artroscópicos ou cirúrgicos em um mamìfero, infertilidade em um mamìfero, de diminuir os nìveis de colesterol, triglicerìdeos, lp(a), ou ldl, de fornecer realce na cognição ou neuroproteção, de contracepção em um mamìfero, e para preparar um composto, e, produto

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL109990A (en) * 1993-06-21 1999-06-20 Lilly Co Eli Materials and methods for screening anti-osteoporosis agents
EP0800530A4 (fr) * 1994-07-20 1998-12-02 Celtrix Pharma Complexe igf/igfbp destines a favoriser la formation osseuse et a reguler le remodelage osseux
HN1996000101A (es) * 1996-02-28 1997-06-26 Inc Pfizer Terapia combinada para la osteoporosis
AU5594398A (en) * 1996-12-09 1998-07-03 Merck & Co., Inc. Methods and compositions for preventing and treating bone loss

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO0076529A2 *

Also Published As

Publication number Publication date
GB9913649D0 (en) 1999-08-11
WO2000076529A3 (fr) 2001-07-12
AU5545400A (en) 2001-01-02
WO2000076529A2 (fr) 2000-12-21
CA2376441A1 (fr) 2000-12-21

Similar Documents

Publication Publication Date Title
RU2327461C2 (ru) Способы лечения и/или подавления прироста массы
TURNER et al. Tamoxifen inhibits osteoclast-mediated resorption of trabecular bone in ovarian hormone-deficient rats
Clemett et al. Raloxifene: a review of its use in postmenopausal osteoporosis
CA2301032C (fr) Procede de prevention et traitement de maladies et troubles induits par oestrogenes
DE60217324T2 (de) Pharmazeutische zusammensetzung für die hormonersatztherapie
RU2132682C1 (ru) Применение антиэстрогенных соединений, а также фармацевтически приемлемых солей и сольватов для уменьшения концентрации глюкозы в крови и фармацевтический препарат
Jerome et al. Decreased bone mass and strength in ovariectomized cynomolgus monkeys (Macaca fascicularis)
JP6532754B2 (ja) エストロゲン関連疾患を治療するまたは予防するための方法
EP0929295A4 (fr)
CZ284522B6 (cs) Způsob a zařízení pro výrobu kompozitní nitě a kompozitních výrobků, získaných z této nitě
BG61524B1 (bg) Използване на бензотиофени за намаляване на холестерола в кръвта
Buelke-Sam et al. The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing
US20080085879A1 (en) Methods of treating estrogen-responsive conditions by orphan nuclear receptor activation
Porter et al. Effects of raloxifene in a guinea pig model for leiomyomas
Williams et al. Effects of estrogen and tamoxifen on serum osteocalcin levels in ovariectomized rats
WO2000076529A2 (fr) Recepteur d'oestrogenes
WO1998043639A1 (fr) Procedes pour traiter la deperdition osseuse
US20060270641A1 (en) Method for chemoprevention of prostate cancer
JP4263264B2 (ja) 解離したエストロゲン活性を有する薬剤を製造するための１１位置換ステロイド化合物の用途
Howell Tamoxifen versus the newer SERMs: what is the evidence?
CZ76699A3 (cs) Způsob léčení postmenopauzálních chorob, včetně osteoporozy
JP2002541223A (ja) エストロゲンレセプター及び骨
Uyar et al. The effect of clomiphene citrate on osteoporosis in ovariectomized rats
JP2001501907A (ja) 骨損失を最小限にする方法
JP2002522389A (ja) 異常骨吸収を治療又は予防するためのｎｋ−１受容体アンタゴニストの使用

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011214

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

17Q First examination report despatched

Effective date: 20021105

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20030516